Date and Recipients

The disclosure is dated 15th July 2026 and is addressed to the Listing Departments of BSE Limited (Scrip Code: 532694) and the National Stock Exchange of India Limited (Symbol: ASMS).

Subject and Context

This is a revised disclosure submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It serves as a correction to an earlier intimation dated 8th April 2026 concerning the company's investment in Huwel Lifesciences Private Limited ("Huwel").

Nature of Revision

The company clarifies that certain particulars in the April 8th disclosure require revision. Specifically, the total amount of investment and the resulting percentage of shareholding were incorrect.

Revised Investment Details

  • Total Investment: The revised total investment made in Huwel is ₹7,50,00,400 (Indian Rupees Seven Crore Fifty Lakhs Four Hundred Only). This corrects the previously stated amount of ₹4,00,00,000.
  • Shareholding Acquired: Pursuant to this investment, Avio Smart Market Stack Limited has acquired 2.06% of the paid-up equity share capital of Huwel.
  • Transaction Details: The company acquired 9,665 equity shares at a price of ₹7,760 per share. This price includes a premium of ₹7,750 per share.
  • Mode of Consideration: The consideration was paid in Cash.
  • Transaction Status: The acquisition has been completed.

Unchanged Terms

The company confirms that all other terms and conditions from the original disclosure remain unchanged. This includes the mode of consideration (cash) and the purpose of the investment.

Purpose and Rationale

The stated object and effect of the acquisition is to derive operational and financial synergies.

Background on Acquired Entity (Huwel Lifesciences Private Limited)

  • Corporate Identification Number (CIN): U33111TG2015PTC097596
  • Date of Incorporation: 10th February 2015
  • Line of Business: Huwel is engaged in the development, manufacturing, and supply of molecular diagnostic kits, medical devices, and in-vitro diagnostic solutions. It serves hospitals, laboratories, and research institutions with products for disease detection and healthcare testing.
  • Location: Patancheru, Telangana, India.
  • Historical Turnover:
  • Financial Year 2022-23: ₹12.11 Crore
  • Financial Year 2023-24: ₹4.94 Crore
  • Financial Year 2024-25: ₹15.74 Crore

Regulatory and Transaction Classifications

  • Related Party Transaction: The disclosure confirms this is not a related party transaction. The promoter/promoter group/group companies have no interest in Huwel.
  • Arm's Length: The acquisition was conducted on an arm's length basis.
  • Government Approvals: No governmental or regulatory approvals were required for this acquisition; it is noted as "Not Applicable".

Compliance

The revised disclosures, pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III, are enclosed as Annexure – A (which is the provided data).